Table 1.
Characteristics of hepatocellular carcinoma patients with portal vein tumor thrombus
| Item | No therapy group (n=51) | TACE group (n=31) | Radiotherapy group (n=10) | P-value |
|---|---|---|---|---|
| Mean age ± SD | 49±11 | 48±15 | 47±16 | 0.794 |
| Sex (M), n (%) | 45 (88%) | 29 (94%) | 9 (90%) | 0.734 |
| Positive for HBeAg, n (%) | 11 (22%) | 6 (19%) | 3 (30%) | 0.777 |
| PLT, 109/L | 245±103 | 259±119 | 301±121 | 0.784 |
| Tbil, μmol/L | 19 (12–28) | 19 (13–30) | 18 (12–33) | 0.975 |
| ALB, g/L | 37±4 | 37±5 | 34±2 | 0.952 |
| ALT, U/L | 49 (27–89) | 46 (28–83) | 42 (20–78) | 0.127 |
| AST, U/L | 47 (25–85) | 44 (20–79) | 45 (25–81) | 0.904 |
| PT, seconds | 14±2 | 13±1 | 13±1 | 0.967 |
| AFP, mg/L | 893 (199–1,210) | 870 (510–1,210) | 972 (674–1,210) | 0.761 |
| Child–Pugh A/B | 47/4 | 30/1 | 10/0 | 0.486 |
| Ascites | 2 (4%) | 1 (3%) | 0 (0%) | 0.816 |
| Tumor size, cm | 12±7 | 10±4 | 11±6 | 0.961 |
| Tumor number (≥3), n (%) | 9 (18%) | 6 (19%) | 3 (30%) | 0.666 |
| Cirrhosis, n (%) | 47 (92%) | 28 (90%) | 9 (90%) | 0.948 |
| Blood loss, mL | 400 (180–650) | 350 (150–600) | 400 (200–650) | 0.713 |
| Operating time, minutes | 240 (180–400) | 280 (200–420) | 260 (180–420) | 0.871 |
| PVTT type, I/II | 30/21 | 17/14 | 6/4 | 0.927 |
Note: Normally distributed data are expressed as mean ± standard deviation, and asymmetrically distributed data are expressed as median (range).
Abbreviations: AFP, alpha-fetoprotein; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HBeAg, hepatitis B e antigen; PLT, platelet count; PT, prothrombin time; PVTT, portal vein tumor thrombus; SD, standard deviation; TACE, transarterial chemoembolization; Tbil, total bilirubin.